Clinical trials
Mild Alzheimer Disease clinical trials
Below are recruiting mild alzheimer disease clinical trials, each written for real people, not researchers. We’re tracking 305 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04123314RecruitingEarly Phase 1
Psilocybin study for depression in mild memory or early Alzheimer’s
This early-phase study tests whether psilocybin (a psychedelic substance) can help with depression in people who have mild memory problems or early Alzheimer’s. The trial also closely monitors safety, thinking changes, mood, and blood pressure before and after dosing.
Baltimore, MarylandAges 18–85 - NCT03687710Enrolling by invitation
Alzheimer’s registry for people with memory concerns or risk
This is a research registry that helps doctors compare how different memory and Alzheimer’s risk groups change over time. It may help researchers learn which people are more likely to develop Alzheimer’s and how to better track early changes.
New York, New YorkAges 18–99 - NCT03653156Recruiting
Aging and brain study for mild memory loss and dementia
This study checks how age affects memory and thinking, and compares people with mild memory problems, Alzheimer’s disease types, vascular dementia, and healthy controls. You may help researchers understand brain changes using thinking tests, MRI scans, and blood or spinal fluid tests.
Hefei, AnhuiAges 18 years+ - NCT03140865Recruiting
Alzheimer’s disease research core for brain and memory testing
This study group collects detailed information from people with normal memory, mild cognitive impairment, or mild Alzheimer’s disease to support Alzheimer’s research. You may need multiple visits, brain scans, and sometimes a spinal fluid sample, with strict health and medication requirements to keep results clear.
Winston-Salem, North CarolinaAges 55 years+ - NCT03089827Enrolling by invitation
Tests how a brain imaging tracer spreads in Alzheimer’s risk
This trial uses a radioactive imaging tracer to see how it moves and settles in the brain in people with risk factors for Alzheimer’s disease. It may help researchers understand which people show tracer patterns linked to Alzheimer’s changes.
Winston-Salem, North CarolinaAges 55 years+ - NCT03233646Recruiting
Retina scans in memory and nerve disorders
This study uses pictures of the back of your eye (retinal imaging) to look for differences in people with neurodegenerative diseases and compares them with people without these conditions. It may help researchers understand eye changes that could connect to brain or nerve health.
Durham, North CarolinaAges 18 years+ - NCT02740634Recruiting
Brain imaging study for Alzheimer's disease
This study uses brain scans to understand Alzheimer's disease and related conditions that affect memory, language, or vision. It looks at how changes in the brain happen over time in people with these diagnoses.
Rochester, MinnesotaAges 21–80 - NCT03082755RecruitingPhase 4
Study sleep agitation and restless legs in Alzheimer’s patients
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
Austin, TexasAges 55 years+ - NCT04436081RecruitingPhase 2
CBD oil without THC for agitation in Alzheimer’s dementia
This trial studies whether a THC-free CBD oil softgel can reduce agitation in people with Alzheimer’s-related dementia. It compares CBD to a control to see if it improves difficult behaviors and is safe over the study period.
Norfolk, VirginiaAges 50–90 - NCT07857759Recruiting
Neck lymph node surgery for early Alzheimer's disease
This study tests whether a microsurgery on lymph nodes in the neck can help clear waste from the brain in people with early Alzheimer's. It might slow down memory loss.
GdanskAges 18 years+ - NCT04114994Recruiting
Memory testing study for adults 50 and older
This study checks how people’s thinking and memory change over time using a specific cognitive test. It may help researchers understand patterns of memory change and supports future research on brain health.
Miami, FloridaAges 50 years+ - NCT07787169RecruitingPhase 1
Study of amyloid-targeting therapies for Alzheimer's disease
This study tests several new experimental medications that target amyloid plaques, the protein clumps linked to Alzheimer's disease. It aims to find out if these treatments are safe and well-tolerated in people with early-stage Alzheimer's and in healthy volunteers.
Anaheim, CaliforniaAges 18–85 - NCT05509387Recruiting
Stronger brain stimulation to improve naming in Alzheimer’s
This trial tests whether a stronger form of gentle brain stimulation (tDCS) can help people with mild to moderate Alzheimer’s improve word-finding (naming). If you qualify, you’ll be assessed before and during the study to see whether the stimulation improves naming ability.
Toronto, OntarioAges 50–90 - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT06732128Recruiting
Nature virtual reality for depression in Alzheimer's disease
This trial tests whether a virtual reality nature experience can help improve mood in people with early-to-moderate Alzheimer's disease. Participants will use a VR headset and a few apps at home, with a caregiver present, over several sessions.
Toronto, OntarioAges 50 years+ - NCT05801380Recruiting
Tracking how well a medicine works in Alzheimer’s patients
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Manila, National Capital RegionAges 65 years+ - NCT06535308RecruitingPhase 1
Testing a new Alzheimer's drug for moderate disease
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Seoul, Jongno-guAges 19–45 - NCT06841848Recruiting
Eye camera test for early Alzheimer's
This study is testing a new eye camera to see if it can help find early signs of Alzheimer's disease. It is for people aged 55 and older who either have mild to moderate Alzheimer's or do not have Alzheimer's.
Rome, ItalyAges 55 years+ - NCT06874231Recruiting
Brain connectivity marker for Alzheimer's disease
This study uses brain scans to find a marker for Alzheimer's disease. It is looking for people with normal memory, mild memory problems, or mild Alzheimer's, and who can undergo a spinal tap and MRI.
Stockholm, SolnaAges 40–85 - NCT07294885Recruiting
Lymphatic surgery for Alzheimer's disease
This study tests a surgical procedure to connect lymph vessels in the neck to veins, which may help clear waste from the brain in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It is for patients who have not improved after at least 3 months of standard care.
ShenyangAges 50–80 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT07213700Recruiting
Alzheimer's disease long-term study
This study follows people with Alzheimer's disease over time to learn more about the condition and improve future care. It is an observational study, meaning participants receive their usual care while researchers collect information.
MelbourneAges 18 years+ - NCT07208344RecruitingEarly Phase 1
Umbilical cord blood infusion for Alzheimer's disease
This early-phase study tests whether infusing donated umbilical cord blood (a source of young immune cells) can help slow Alzheimer's disease. It is for people aged 50–75 with mild to moderate Alzheimer's who have a caregiver and are otherwise generally healthy.
Hefei, AnhuiAges 50–75 - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85
Hear when a new Mild Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild alzheimer disease?
- Yes. Clin2 currently lists 305 recruiting mild alzheimer disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild alzheimer disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild alzheimer disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.